Ibogaine Therapy and the Seizure Question: Epilepsy, Migraine, and the Screening Nobody Talks About

If you read enough about ibogaine therapy, you come away thinking the entire risk profile lives in one organ.

That is not an unreasonable impression. The cardiac story is genuinely the dominant one: ibogaine blocks the hERG potassium channel, prolongs the QT interval, and the fatalities documented in the literature cluster heavily around arrhythmia. Any clinic worth considering will run an ECG, correct your electrolytes, and watch a monitor for a day and a half. Our full overview of what ibogaine therapy involves treats the cardiac screen as the non-negotiable core of the process, and that is correct.

But there is a second nervous system in the room, and it gets a fraction of the attention.

Ibogaine is a central nervous system drug. It produces ataxia, tremor, profound alterations of consciousness lasting well past 24 hours, and — in the case series and the animal literature — occasional seizures. If you have epilepsy, a seizure disorder, a history of withdrawal seizures, or even chronic migraine, you are carrying a set of variables that the standard cardiac workup was not designed to catch.

This article is about that gap. It is not a reason to abandon the idea of ibogaine therapy. It is a set of questions to put in front of a clinic, and a way of understanding why the answers matter.

---

Why a seizure during ibogaine is not an ordinary seizure

Start here, because everything else follows from it.

In an ordinary setting, a generalized tonic-clonic seizure is frightening but usually self-limiting. Protect the head, time it, let it stop, manage the aftermath. Status epilepticus is the emergency; a single seizure usually is not.

Now put that same seizure inside an ibogaine session and watch what changes.

The patient already has a prolonged QT interval. That is not an accident — it is the pharmacology working as expected. Ibogaine reliably stretches the QT, often substantially, for many hours. A seizure adds catecholamine surge, acidosis, and often vomiting on top of a myocardium that is already electrically vulnerable. The two problems compound rather than sit side by side.

Half the obvious responses also prolong QT. This is the trap, and it is the same shape as the perioperative problem we have written about before: the drug you would instinctively reach for makes the underlying issue worse. Ondansetron — the default anti-emetic in almost every clinical setting, and ibogaine makes people nauseated — is a known QT prolonger, to the point that the FDA withdrew the 32 mg IV dose in 2012. Several antipsychotics used for acute agitation prolong QT. Some antiarrhythmics do too. The set of drugs that are safe to give an ibogaine patient in a neurological emergency is narrower than most people assume, and a clinic should be able to tell you what is on their list and what is off it.

Electrolytes are already being manipulated. Good clinics correct magnesium and potassium before dosing precisely because those corrections buy QT margin. A seizure with vomiting can undo hours of that work in minutes.

And you cannot see it. This is the part that unsettles clinicians most when it is pointed out. Ibogaine produces ataxia, disorientation, motor incoordination, and long stretches of altered consciousness. A post-ictal state looks like that. Someone who is confused, unsteady, and non-communicative at hour eight of an ibogaine session is expected to look that way. The clinical signal that would normally tell staff "something just happened" is buried inside the drug's ordinary presentation. Unwitnessed seizures can therefore pass unrecognized — which is one of several strong arguments for continuous observation rather than periodic check-ins.

---

The withdrawal seizure problem, which is much more common than epilepsy

Most people who arrive for ibogaine therapy do not have epilepsy. A great many of them have something that produces the same acute risk: withdrawal.

Alcohol withdrawal and benzodiazepine withdrawal both cause seizures. This is not exotic — it is one of the best-characterized facts in addiction medicine. Withdrawal seizures typically appear in the first 48 hours after the last drink for alcohol, and can appear considerably later and less predictably for long half-life benzodiazepines.

Now consider the setup that ibogaine therapy creates.

Clinics generally require patients to be off benzodiazepines before dosing, for good reasons — GABAergic sedatives interfere with the treatment and complicate the picture. So a patient tapers. Then they travel. Then they arrive, often stressed, often sleep-deprived, often having under-reported how much they were actually taking. And then they receive a compound that is itself associated with seizure activity at higher exposures, while their withdrawal risk window may still be open.

That is a genuinely hazardous convergence, and it is created by the treatment pathway rather than by any underlying disease. The questions it generates are practical:

• Who supervised the taper, and over what timeline? A benzodiazepine taper that respects withdrawal seizure risk is measured in weeks, not days. A clinic that tells you to "stop a few days before" is not managing this.
• How honest was the intake about dose? Under-reporting benzodiazepine and alcohol use is extremely common and it is the single input that most changes this risk calculation. There is no upside to shading the number.
• What is the gap between last use and dosing, and who decided it was long enough?
• Is the clinic willing to delay? The correct answer to an incomplete taper is to postpone, and a program that treats the scheduled date as fixed is prioritizing the wrong thing.

Our detailed piece on benzodiazepines and ibogaine goes deeper into the tapering side of this specifically.

---

If you actually have epilepsy: the anticonvulsant interaction problem

For patients with a diagnosed seizure disorder, the issue splits into two separate problems that get confused with each other.

Problem one: you probably should not stop your anticonvulsant. Abrupt withdrawal of an antiepileptic drug is itself a well-known seizure trigger. So "just come off it before treatment" is not a safe default.

Problem two: several anticonvulsants substantially change how ibogaine is metabolized. Ibogaine is metabolized primarily by CYP2D6 into noribogaine, its long-lived active metabolite, with contributions from other enzymes including CYP3A4. That pathway is where the interactions live — and it is the same pathway that drives most of ibogaine's other drug interactions. Our page on noribogaine and ibogaine metabolism explains why the metabolite matters as much as the parent compound.

The older anticonvulsants are the ones to flag hardest. Carbamazepine, phenytoin, and phenobarbital are potent enzyme inducers — they upregulate hepatic metabolism broadly. An induced patient may clear a given dose very differently from an uninduced one, which undermines the assumption behind any standard weight-based protocol. Carbamazepine additionally has its own cardiac conduction effects.

Newer agents behave differently. Levetiracetam is largely renally cleared and metabolically quiet, which makes it a comparatively less complicated companion. Valproate and lamotrigine sit in between, with their own considerations. None of this makes any particular combination safe or unsafe on paper — it makes it a question that requires an actual pharmacology review by an actual clinician, using something more rigorous than a web search. A clinic that cannot describe how your specific anticonvulsant affects their dosing plan has not done that review.

There is also the CYP2D6 genotype layer sitting underneath all of it. Poor metabolizers clear ibogaine slowly and are exposed for longer at higher concentrations. Stack a poor metabolizer phenotype with an enzyme-inhibiting comedication and you get exposures well outside what the protocol assumed. This is worth checking regardless of neurological history; you can start with our medication interaction checker and the broader medication interactions overview.

---

Migraine: the quiet one

Migraine feels like it should be irrelevant here. It is not, for three reasons — and it is worth raising precisely because almost nobody thinks to disclose it.

Triptans are serotonergic. Sumatriptan, rizatriptan and the rest are 5-HT1 agonists. Ibogaine and noribogaine have meaningful serotonergic activity, including serotonin transporter effects. This is the same class of concern that drives the SSRI conversation, and it is why SSRI tapering is a standard part of ibogaine preparation. Triptans are usually taken as-needed rather than daily, which means patients frequently do not list them as a medication at all. They should.

Common migraine preventives are cardiovascular drugs. Propranolol is one of the most widely prescribed migraine preventives in the world, and it is a beta-blocker. Ibogaine causes bradycardia. Layering a beta-blocker onto a drug that slows the heart, in a patient whose QT is being deliberately stretched, is a combination that deserves a specific conversation rather than a shrug. Verapamil, also used in cluster headache and migraine prevention, is a calcium channel blocker with its own conduction effects — and a CYP3A4 inhibitor besides.

Ergotamines are vasoconstrictors with a long and unfriendly interaction profile, and belong on any disclosure list.

There is a fourth, softer point. Severe migraine and post-ibogaine headache are hard to tell apart, and migraine with aura in a patient who is already having profound visual phenomena is diagnostically messy. It does not make treatment inappropriate. It makes it harder for staff to interpret what they are seeing, which is worth their knowing in advance.

---

What a real neurological screen looks like

If you take one practical thing from this article, take this list. These are things a clinic should be doing, and things you can ask about directly.

Before you go:

• A neurological history that specifically asks about seizures, febrile seizures in childhood, head injury with loss of consciousness, epilepsy in first-degree relatives, and migraine.
• A complete medication list that includes as-needed drugs and supplements, not just daily prescriptions.
• An honest accounting of alcohol and benzodiazepine use, with the taper supervised by a prescriber rather than improvised.
• Baseline bloods including magnesium and potassium — the same correction that buys cardiac margin also matters here, and liver and kidney function screening governs how well you clear the drug at all.
• Neurology input if you have an active seizure disorder. Not the clinic's opinion about your neurology — your neurologist's opinion about the clinic's plan.

Questions to ask the clinic:

• What is your protocol if a patient seizes during treatment, drug by drug? You are listening for whether they have thought about QT-prolonging agents. If ondansetron is their reflex anti-emetic and they have never considered the interaction, that is informative.
• Is observation continuous, or intermittent? Given that post-ictal states hide inside ibogaine's normal presentation, intermittent is a real limitation.
• How do you distinguish ataxia from a post-ictal state?
• Have you treated patients on anticonvulsants before, and how did you adjust?
• Is there benzodiazepine access on site for status epilepticus, and who is authorized to give it? There is genuine tension here — the sedative you may need in an emergency is the drug class you were told to stop. A clinic should be able to hold both facts at once.
• What is the distance and transfer time to a facility with neurology and cardiology?

Our clinic evaluation guide and pre-screening tool cover the broader version of this vetting process.

---

The honest summary

The evidence base here is thin, and you should be suspicious of anyone who tells you otherwise in either direction. Seizures appear in ibogaine case reports and in animal work at high exposures, but there is no controlled trial establishing a rate, no dose-response curve you can rely on, and no consensus protocol for epileptic patients. Anyone quoting you a precise risk figure is inventing it. You can read more about why the evidence looks like this in our overview of ibogaine safety, risks and screening protocols.

What can be said with more confidence is structural. A seizure during ibogaine therapy is worse than a seizure elsewhere, for reasons that are mechanical rather than speculative: the QT is already prolonged, the rescue drugs are constrained, the electrolytes are already being defended, and the clinical presentation is camouflaged. Withdrawal seizure risk is created by the treatment pathway itself and is far more common than epilepsy among the people seeking this treatment. Anticonvulsants change ibogaine metabolism in ways that undermine standard dosing. And migraine drags in serotonergic and cardiovascular medications that patients routinely fail to disclose.

None of that is a prohibition. It is a screen — the neurological counterpart to the cardiac screen that the field already takes seriously. The clinics that will do well by you are the ones that can discuss it without getting defensive.

---

This article is for education only and is not medical advice. Ibogaine is a Schedule I substance in the United States and carries documented risks of fatal cardiac arrhythmia. Never start, stop, or change a prescribed medication — particularly an anticonvulsant, benzodiazepine, or antidepressant — without direct supervision from the prescribing clinician. Abrupt discontinuation of antiepileptic or benzodiazepine medication can itself cause life-threatening seizures. Ibogaine Treatment Guide is an independent educational resource and is not a treatment provider. If you are in crisis, call or text 988 (Suicide & Crisis Lifeline, US) or contact your local emergency services.